secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001854270-25-000008
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio appoints Jay Cross as CFO and Faraz Siddiqui as SVP Technical Operations
--------------------------------------------------------------------------------

- Jay Cross appointed CFO effective March 3, 2025; base salary $465k, annual target bonus 40%, sign-on bonus $50k repayable if leaving before 14 months.
- Stock option for 174,200 shares (or 44,000 if stockholder proposal fails) under 2022 Inducement Plan; four-year vesting.
- Faraz Siddiqui joined as SVP Technical Operations in Jan 2025; oversees manufacturing, supply chain; previously at IGM Biosciences, Instil Bio, Kite Pharma, Genentech.
- CEO Timothy Lu served as interim principal financial officer from Jan 31 until 10-K filing when Cross assumes role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000008/0001854270-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000008/snti-20250223.htm
  HTML page:      https://secwatch.observer/filing/0001854270-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer